Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis - PubMed (original) (raw)

Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis

W Paxton et al. J Virol. 1993 Dec.

Abstract

The product of the vpr open reading frame of human immunodeficiency virus type 1 (HIV-1) is a 15-kDa, arginine-rich protein that is present in virions in molar quantities equivalent to that of Gag. We report here the results of our investigations into the mechanism by which Vpr is incorporated into virions during assembly in infected cells. For these studies we used an expression vector encoding a Vpr molecule fused at its amino terminus to a nine-amino-acid peptide from influenza virus hemagglutinin. The tagged Vpr expression vector and a vpr mutant HIV-1 provirus were used to cotransfect COS cells, and the resulting virions were tested for the presence of the tagged protein on immunoblots probed with monoclonal antibody against the hemagglutinin peptide. The COS-produced virions were found to contain readily detectable amounts of tagged Vpr and smaller amounts of a putative tagged Vpr dimer. Infectivity of the particles was not altered by incorporation of tagged Vpr. Our results using this system in combination with mutant HIV-1 proviruses suggested that incorporation of Vpr into virions requires the carboxy-terminal Gag protein of HIV-1 (p6) but not gp160, Pol, or genomic viral RNA. In addition, analysis of mutated, tagged Vpr molecules suggested that amino acids near the carboxy terminus (amino acids 84 to 94) are required for incorporation of Vpr into HIV-1 virions. The single cysteine residue near the carboxy terminus was required for production of a stable protein. Arginine residues tested were not important for incorporation or stability of tagged Vpr. These results suggested a novel strategy for blocking HIV-1 replication.

PubMed Disclaimer

Cited by

A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24.
Nyame P, Togami A, Yoshida T, Masunaga T, Begum MM, Terasawa H, Monde N, Tahara Y, Tanaka R, Tanaka Y, Appiah-Kubi J, Amesimeku WAO, Hossain MJ, Otsuka M, Yoshimura K, Ikeda T, Sawa T, Satou Y, Fujita M, Maeda Y, Tateishi H, Monde K. Nyame P, et al. J Biol Chem. 2024 Sep;300(9):107701. doi: 10.1016/j.jbc.2024.107701. Epub 2024 Aug 22. J Biol Chem. 2024. PMID: 39173946 Free PMC article.
HIV-1 Vpr-induced DNA damage activates NF-κB through ATM-NEMO independent of cell cycle arrest.
Sandoval C, Nisson K, Fregoso OI. Sandoval C, et al. bioRxiv [Preprint]. 2024 Jan 25:2023.05.23.541990. doi: 10.1101/2023.05.23.541990. bioRxiv. 2024. PMID: 37292767 Free PMC article. Updated. Preprint.
Multimodal Functionalities of HIV-1 Integrase.
Engelman AN, Kvaratskhelia M. Engelman AN, et al. Viruses. 2022 Apr 28;14(5):926. doi: 10.3390/v14050926. Viruses. 2022. PMID: 35632668 Free PMC article. Review.
The HIV-1 Viral Protease Is Activated during Assembly and Budding Prior to Particle Release.
Tabler CO, Wegman SJ, Chen J, Shroff H, Alhusaini N, Tilton JC. Tabler CO, et al. J Virol. 2022 May 11;96(9):e0219821. doi: 10.1128/jvi.02198-21. Epub 2022 Apr 19. J Virol. 2022. PMID: 35438536 Free PMC article.
Advances in HIV-1 Assembly.
Lerner G, Weaver N, Anokhin B, Spearman P. Lerner G, et al. Viruses. 2022 Feb 26;14(3):478. doi: 10.3390/v14030478. Viruses. 2022. PMID: 35336885 Free PMC article. Review.

References

1. J Virol. 1990 Jun;64(6):3097-9 - PubMed
1. J Virol. 1990 Jun;64(6):2743-50 - PubMed
1. J Virol. 1990 Oct;64(10):5230-4 - PubMed
1. J Virol. 1990 Nov;64(11):5688-93 - PubMed
1. Proc Natl Acad Sci U S A. 1990 Oct;87(20):8080-4 - PubMed

Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis - PubMed (original) (raw)